CTGov Compliance My Organizations

Compliance Rate

Compliance Rate 0%

Compliant submissions 0

Incompliant submissions 0

Total trials 0

My Organizations' Clinical Trials

Showing 75 of 124 entries

View as:

Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008)

Phase: N/A Priority: Normal

NCT ID: NCT04772287 Org: User:

Start: 03/31/21 End: 12/30/27 Due: 12/30/28

Efficacy and Safety of Sitafloxacin in the Treatment of Acute Exacerbation of Bronchiectasis in Adults

Phase: N/A Priority: Normal

NCT ID: NCT05313750 Org: User:

Start: 06/30/21 End: 06/30/24 Due: 06/30/25

The Efficiency of Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung Cancer

Phase: N/A Priority: Normal

NCT ID: NCT05496166 Org: User:

Start: 08/01/23 End: 08/01/30 Due: 08/01/31

Cytokine Profile of Allergic Bronchopulmonary Aspergillosis

Phase: N/A Priority: Normal

NCT ID: NCT03643185 Org: User:

Start: 12/31/14 End: 05/04/21 Due: 05/04/22

EGFR-TKI With Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism

Phase: N/A Priority: Normal

NCT ID: NCT02859077 Org: User:

Start: 08/31/16 End: 07/31/18 Due: 07/31/19

The Establishment of China Bronchiectasis Registry and Research Collaboration

Phase: N/A Priority: Normal

NCT ID: NCT03643653 Org: User:

Start: 01/01/19 End: 12/31/25 Due: 12/31/26

Systematic Sampling of Lymph Nodes vs. Lymphadenectomy According to Intraoperative Frozen Pathology for Pulmonary Invasive Adenocarcinoma With Ground-glass Opacity

Phase: N/A Priority: Normal

NCT ID: NCT03322826 Org: User:

Start: 12/08/17 End: 10/28/23 Due: 10/28/24

VATS VS. Open Thoracic Surgery for Stage II - III Lung Cancer

Phase: N/A Priority: Normal

NCT ID: NCT04009915 Org: User:

Start: 06/01/19 End: 12/30/25 Due: 12/30/26

Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer

Phase: N/A Priority: Normal

NCT ID: NCT04728724 Org: User:

Start: 09/10/22 End: 12/31/27 Due: 12/31/28

Combined Simvastatin and Albumin Paclitaxel in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy

Phase: N/A Priority: Normal

NCT ID: NCT04698941 Org: User:

Start: 07/25/21 End: 12/30/22 Due: 12/30/23

Long-term Impact of Inhaled Tobramycin for Pseudomonas Aeruginosa Eradication in Bronchiectasis (ERASE II)

Phase: N/A Priority: Normal

NCT ID: NCT06760273 Org: User:

Start: 10/16/24 End: 12/31/27 Due: 12/31/28

Exploring the Neo-Adjuvant Therapy Effects on Lung Cancer Through Monitoring and Assessment of Tumor Environment

Phase: N/A Priority: Normal

NCT ID: NCT05857800 Org: User:

Start: 05/25/23 End: 05/25/33 Due: 05/25/34

Airway Clearance and Bronchoalveolar Lavage for Bronchiectasis Patients With Exacerbation

Phase: N/A Priority: Normal

NCT ID: NCT03643302 Org: User:

Start: 02/01/18 End: 03/18/19 Due: 03/18/20

Perioperative Immunotherpay Versus Adjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer

Phase: N/A Priority: Normal

NCT ID: NCT06109402 Org: User:

Start: 12/20/23 End: 11/01/30 Due: 11/01/31

Adjuvant Benmelstobart for Stage IB, Grade 3 Invasive Lung Adenocarcinoma

Phase: N/A Priority: Normal

NCT ID: NCT06528847 Org: User:

Start: 06/05/24 End: 06/30/30 Due: 06/30/31

Chromosomal Instability as a Surrogate Biomarker of Drug Resistance in Immunotherapy for Lung Cancer Patients

Phase: N/A Priority: Normal

NCT ID: NCT04203095 Org: User:

Start: 11/10/19 End: 11/11/21 Due: 11/11/22

The Impact of Communication With Healthcare Providers Via WeChat on Survival Outcomes for Lung Cancer Patietns

Phase: N/A Priority: Normal

NCT ID: NCT06592430 Org: User:

Start: 10/01/24 End: 10/01/26 Due: 10/01/27

Induction Therapy With Serplulimab Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer

Phase: N/A Priority: Normal

NCT ID: NCT06591910 Org: User:

Start: 09/20/24 End: 09/20/30 Due: 09/20/31

Deep Learning Signature for Predicting Aggressive Histological Pattern in Resected Non-small Cell Lung Cancer

Phase: N/A Priority: Normal

NCT ID: NCT05925738 Org: User:

Start: 05/01/23 End: 10/31/23 Due: 10/31/24

Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer

Phase: N/A Priority: Normal

NCT ID: NCT05766800 Org: User:

Start: 03/14/23 End: 04/01/27 Due: 04/01/28

Efficiency and Safety of Microwave Ablation Plus Immune Checkpoint Inhibitor for Patients With Multiple Primary Lung Cancer: A Open, Multi-center, Phase II Clinical Trial

Phase: N/A Priority: Normal

NCT ID: NCT05053802 Org: User:

Start: 03/21/21 End: 09/30/27 Due: 09/30/28

Efficacy and Safety of Inhaled Bronchodilator in Non-CF Bronchiectasis With Airflow Limitation

Phase: N/A Priority: Normal

NCT ID: NCT04509661 Org: User:

Start: 09/01/20 End: 06/01/24 Due: 06/01/25

Comparison of Neoadjuvant Cadonilimab Versus Chemotherapy Combined With PD-1 in the Treatment of Resectable Non-Small Cell Lung Cancer With High PD-L1 Expression: A Single-Center, Randomized, Exploratory Clinical Study

Phase: N/A Priority: Normal

NCT ID: NCT06946836 Org: User:

Start: 04/21/25 End: 05/11/31 Due: 05/11/32

A Study of Ultrashort PRS Regimen V in the Treatment of MDR-TB

Phase: N/A Priority: Normal

NCT ID: NCT05278988 Org: User:

Start: 04/01/21 End: 10/30/24 Due: 10/30/25

EGFR-TKI With/Without Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism

Phase: N/A Priority: Normal

NCT ID: NCT03002844 Org: User:

Start: 12/31/16 End: 12/31/18 Due: 12/31/19

Title	NCT ID	Organization	User	Status	Start Date	End Date	Reporting Due Date	Last Checked	User Role	Org Created
Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008)	NCT04772287	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2021-03-31	2027-12-30	2028-12-30	-	-	2025-07-14
Efficacy and Safety of Sitafloxacin in the Treatment of Acute Exacerbation of Bronchiectasis in Adults	NCT05313750	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2021-06-30	2024-06-30	2025-06-30	-	-	2025-07-14
The Efficiency of Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung Cancer	NCT05496166	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2023-08-01	2030-08-01	2031-08-01	-	-	2025-07-14
Cytokine Profile of Allergic Bronchopulmonary Aspergillosis	NCT03643185	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2014-12-31	2021-05-04	2022-05-04	-	-	2025-07-14
EGFR-TKI With Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism	NCT02859077	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2016-08-31	2018-07-31	2019-07-31	-	-	2025-07-14
The Establishment of China Bronchiectasis Registry and Research Collaboration	NCT03643653	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2019-01-01	2025-12-31	2026-12-31	-	-	2025-07-14
Systematic Sampling of Lymph Nodes vs. Lymphadenectomy According to Intraoperative Frozen Pathology for Pulmonary Invasive Adenocarcinoma With Ground-glass Opacity	NCT03322826	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2017-12-08	2023-10-28	2024-10-28	-	-	2025-07-14
VATS VS. Open Thoracic Surgery for Stage II - III Lung Cancer	NCT04009915	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2019-06-01	2025-12-30	2026-12-30	-	-	2025-07-14
Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer	NCT04728724	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2022-09-10	2027-12-31	2028-12-31	-	-	2025-07-14
Combined Simvastatin and Albumin Paclitaxel in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy	NCT04698941	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2021-07-25	2022-12-30	2023-12-30	-	-	2025-07-14
Long-term Impact of Inhaled Tobramycin for Pseudomonas Aeruginosa Eradication in Bronchiectasis (ERASE II)	NCT06760273	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2024-10-16	2027-12-31	2028-12-31	-	-	2025-07-14
Exploring the Neo-Adjuvant Therapy Effects on Lung Cancer Through Monitoring and Assessment of Tumor Environment	NCT05857800	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2023-05-25	2033-05-25	2034-05-25	-	-	2025-07-14
Airway Clearance and Bronchoalveolar Lavage for Bronchiectasis Patients With Exacerbation	NCT03643302	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2018-02-01	2019-03-18	2020-03-18	-	-	2025-07-14
Perioperative Immunotherpay Versus Adjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer	NCT06109402	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2023-12-20	2030-11-01	2031-11-01	-	-	2025-07-14
Adjuvant Benmelstobart for Stage IB, Grade 3 Invasive Lung Adenocarcinoma	NCT06528847	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2024-06-05	2030-06-30	2031-06-30	-	-	2025-07-14
Chromosomal Instability as a Surrogate Biomarker of Drug Resistance in Immunotherapy for Lung Cancer Patients	NCT04203095	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2019-11-10	2021-11-11	2022-11-11	-	-	2025-07-14
The Impact of Communication With Healthcare Providers Via WeChat on Survival Outcomes for Lung Cancer Patietns	NCT06592430	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2024-10-01	2026-10-01	2027-10-01	-	-	2025-07-14
Induction Therapy With Serplulimab Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer	NCT06591910	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2024-09-20	2030-09-20	2031-09-20	-	-	2025-07-14
Deep Learning Signature for Predicting Aggressive Histological Pattern in Resected Non-small Cell Lung Cancer	NCT05925738	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2023-05-01	2023-10-31	2024-10-31	-	-	2025-07-14
Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer	NCT05766800	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2023-03-14	2027-04-01	2028-04-01	-	-	2025-07-14
Efficiency and Safety of Microwave Ablation Plus Immune Checkpoint Inhibitor for Patients With Multiple Primary Lung Cancer: A Open, Multi-center, Phase II Clinical Trial	NCT05053802	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2021-03-21	2027-09-30	2028-09-30	-	-	2025-07-14
Efficacy and Safety of Inhaled Bronchodilator in Non-CF Bronchiectasis With Airflow Limitation	NCT04509661	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2020-09-01	2024-06-01	2025-06-01	-	-	2025-07-14
Comparison of Neoadjuvant Cadonilimab Versus Chemotherapy Combined With PD-1 in the Treatment of Resectable Non-Small Cell Lung Cancer With High PD-L1 Expression: A Single-Center, Randomized, Exploratory Clinical Study	NCT06946836	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2025-04-21	2031-05-11	2032-05-11	-	-	2025-07-14
A Study of Ultrashort PRS Regimen V in the Treatment of MDR-TB	NCT05278988	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2021-04-01	2024-10-30	2025-10-30	-	-	2025-07-14
EGFR-TKI With/Without Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism	NCT03002844	Shanghai Pulmonary Hospital, Shanghai, China	user2@example.com	None	2016-12-31	2018-12-31	2019-12-31	-	-	2025-07-14

Compliance Rate

My Organizations' Clinical Trials

Appearance